First Time Loading...

AstraZeneca PLC
LSE:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
LSE:AZN
Watchlist
Price: 12 318 GBX -0.42% Market Closed
Updated: May 14, 2024

Earnings Call Transcript

Earnings Call Transcript
2022-Q4

from 0
Pascal Soriot
executive

2022 was a year of continued strong company performance and execution of our long-term growth strategy. Our pioneering science was evident across all therapy areas, and I'm really proud of what we were able to achieve for patients around the world.

In 2023, we expect to see another year of double-digit revenue growth, excluding our COVID-19 medicines as we bring more medicines to more patients than ever before. And we plan to initiate more than 30 Phase III trials this year, 10 of which have blockbuster potential. And with our continued progress, we are on track to deliver industry-leading growth for 2025 and beyond and deliver at least 15 new medicines before the end of the decade.

My thanks to all of our team for the part they played in achieving our strong results and for continuing to unlock the power of what science can do for people, society and the planet.